NASDAQ:AUPH - Aurinia Pharmaceuticals Stock Price, Forecast & News

Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) posted its quarterly earnings data on Thursday, November, 14th. The biotechnology company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.02. The biotechnology company earned $0.23 million during the quarter, compared to analysts' expectations of $0.05 million. Aurinia Pharmaceuticals had a negative net margin of 19,483.96% and a negative return on equity of 50.79%. View Aurinia Pharmaceuticals' Earnings History.

Aurinia Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 17th 2020. View Earnings Estimates for Aurinia Pharmaceuticals.

8 Wall Street analysts have issued 12 month price objectives for Aurinia Pharmaceuticals' stock. Their forecasts range from $11.00 to $32.00. On average, they anticipate Aurinia Pharmaceuticals' share price to reach $22.29 in the next year. This suggests a possible upside of 9.8% from the stock's current price. View Analyst Price Targets for Aurinia Pharmaceuticals.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aurinia Pharmaceuticals.

Media coverage about AUPH stock has trended extremely negative recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aurinia Pharmaceuticals earned a daily sentiment score of -4.3 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals saw a increase in short interest in January. As of January 31st, there was short interest totalling 5,830,000 shares, an increase of 6.0% from the January 15th total of 5,500,000 shares. Based on an average trading volume of 3,420,000 shares, the days-to-cover ratio is currently 1.7 days. Approximately 7.0% of the shares of the stock are sold short. View Aurinia Pharmaceuticals' Current Options Chain.

Some companies that are related to Aurinia Pharmaceuticals include Catalent (CTLT), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Dr.Reddy's Laboratories (RDY), ACADIA Pharmaceuticals (ACAD), Reata Pharmaceuticals (RETA), Ascendis Pharma A/S (ASND), The Medicines (MDCO), Horizon Therapeutics (HZNP), Amarin (AMRN), United Therapeutics (UTHR), Global Blood Therapeutics (GBT), Evotec (EVTCY) and BridgeBio Pharma (BBIO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Cara Therapeutics (CARA), Micron Technology (MU), Array Biopharma (ARRY), Exelixis (EXEL), Novavax (NVAX), Corbus Pharmaceuticals (CRBP) and Synergy Pharmaceuticals (SGYP).

Aurinia Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (7.18%), Point72 Asset Management L.P. (3.22%), Franklin Resources Inc. (1.19%), Perceptive Advisors LLC (0.64%), Goldman Sachs Group Inc. (0.56%) and Renaissance Technologies LLC (0.52%).

AUPH stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Franklin Resources Inc., Victory Capital Management Inc., SG Americas Securities LLC, Patriot Financial Group Insurance Agency LLC, Bank of Montreal Can, ProShare Advisors LLC and Tower Research Capital LLC TRC .

AUPH stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Point72 Asset Management L.P., Perceptive Advisors LLC, Renaissance Technologies LLC, Ikarian Capital LLC, Broadfin Capital LLC, Crawford Lake Capital Management LLC and Schonfeld Strategic Advisors LLC.

Shares of AUPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AUPH stock can currently be purchased for approximately $20.30.

Aurinia Pharmaceuticals has a market capitalization of $2.27 billion and generates $460,000.00 in revenue each year. The biotechnology company earns $-64,120,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. Aurinia Pharmaceuticals employs 39 workers across the globe.View Additional Information About Aurinia Pharmaceuticals.

The official website for Aurinia Pharmaceuticals is http://www.auriniapharma.com/.

Aurinia Pharmaceuticals' mailing address is 1203-4464 MARKHAM STREET, VICTORIA A1, V8Z 7X8. The biotechnology company can be reached via phone at 250-744-2487 or via email at [email protected]